Коморбидная тревога у женщин с менопаузой различного генеза

1. World Health Organization. Mental health atlas 2024. Geneva: World Health Organization; 2025. Available at: https://iris.who.int/handle/10665/375820
2. GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022; 9(2): 137-50. https://dx.doi.org/10.1016/S2215-0366(21)00395-3
3. Wang J., Guan X., Tao N. GBD: incidence rates and prevalence of anxiety disorders, depression and schizophrenia in countries with different SDI levels, 1990-2021. Front. Public Health. 2025; 13: 1556981. https://dx.doi.org/10.3389/fpubh.2025.1556981
4. Fan Y., Fan A., Yang Z., Fan D. Global burden of mental disorders in 204 countries and territories, 1990-2021: results from the global burden of disease study 2021. BMC Psychiatry. 2025; 25(1): 486. https://dx.doi.org/10.1186/s12888-025-06932-y
5. Collaborators C-MD. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. Lancet. 2021; 398(10312): 1700-12. https://dx.doi.org/10.1016/S0140-6736(21)02143-7
6. Daly M., Sutin A.R., Robinson E. Longitudinal changes in mental health and the COVID-19 pandemic: evidence from the UK household longitudinal study. Psychol. Med. 2022; 52(13): 2549-58. https://dx.doi.org/10.1017/S0033291720004432
7. Brown L., Hunter M.S., Chen R., Crandall C.J., Gordon J.L., Mishra G.D. et al. Promoting good mental health over the menopause transition. Lancet. 2024; 403(10430): 969-83. https://dx.doi.org/10.1016/S0140-6736(23)02801-5
8. Maeng L.Y., Milad M.R. Sex differences in anxiety disorders: interactions between fear, stress, and gonadal hormones. Horm. Behav. 2015; 76: 106-17. https://dx.doi.org/10.1016/j.yhbeh.2015.04.002
9. Burani K., Nelson B.D. Gender differences in anxiety: the mediating role of sensitivity to unpredictable threat. Int. J. Psychophysiol. 2020; 153: 127-34. https://dx.doi.org/10.1016/j.ijpsycho.2020.05.001
10. Li S., Jia Z., Zhang Z., Li Y., Ding Y., Qin Z. et al. Effect of gender on the association between cumulative cardiovascular risk factors and depression: results from the US National Health and Nutrition Examination Survey. Gen. Psychiatr. 2023; 36(4): e101063. https://dx.doi.org/10.1136/gpsych-2023-101063
11. Rubinow D.R., Schmidt P.J. Sex differences and the neurobiology of affective disorders. Neuropsychopharmacology. 2019; 44(1): 111-28. https://dx.doi.org/10.1038/s41386-018-0148-z
12. Koller D., Pathak G.A., Wendt F.R., Tylee D.S., Levey D.F., Overstreet C. et al. Epidemiologic and genetic associations of endometriosis with depression, anxiety, and eating disorders. JAMA Netw. Open. 2023; 6(1): e2251214. https://dx.doi.org/10.1001/jamanetworkopen.2022.51214
13. DeJean D., Giacomini M., Vanstone M., Brundisini F. Patient experiences of depression and anxiety with chronic disease: a systematic review and qualitative meta-synthesis. Ont. Health Technol. Assess Ser. 2013; 13(16): 1-33.
14. Wen J., Wang W., Liu K., Sun X., Zhou J., Hu H. et al. The psychological side of menopause: evidence from the comorbidity network of menopausal, anxiety, and depressive symptoms. Menopause. 2024; 31(10): 897-904. https://dx.doi.org/10.1097/GME.0000000000002406
15. Cyranowski J.M., Schott L.L., Kravitz H.M., Brown C., Thurston R.C., Joffe H. et al. Psychosocial features associated with lifetime comorbidity of major depression and anxiety disorders among a community sample of mid-life women: the SWAN mental health study. Depress. Anxiety. 2012; 29(12): 1050-7. https://dx.doi.org/10.1002/da.21990
16. Alblooshi S., Taylor M., Gill N. Does menopause elevate the risk for developing depression and anxiety? Results from a systematic review. Australas. Psychiatry. 2023; 31(2): 165-73. https://dx.doi.org/10.1177/10398562231165439
17. Kalra B., Kalra S., Bhattacharya S., Dhingra A. Menopause distress: a person centered definition. J. Pak. Med. Assoc. 2020; 70(12(B)): 2481-3.
18. Andreescu C., Lee S. Anxiety disorders in the elderly. Adv. Exp. Med. Biol. 2020; 1191: 561-76. https://dx.doi.org/10.1007/978-981-32-9705-0_28
19. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Генерализованное тревожное расстройство. 2024.
20. Shawon M.S.R., Hossain F.B., Hasan M., Rahman M.R. Gender differences in the prevalence of anxiety and depression and care seeking for mental health problems in Nepal: analysis of nationally representative survey data. Glob. Ment. Health. (Camb). 2024; 11: e46. https://dx.doi.org/10.1017/gmh.2024.37
21. Васенина Е.Е. Гендерные особенности тревожных расстройств. Журнал неврологии и психиатрии им. С.С. Корсакова. 2023; 123(10): 48-53.
22. Altemus M., Sarvaiya N., Neill Epperson C. Sex differences in anxiety and depression clinical perspectives. Front. Neuroendocrinol. 2014; 35(3): 320-30. https://dx.doi.org/10.1016/j.yfrne.2014.05.004
23. Farhane-Medina N.Z., Luque B., Tabernero C., Castillo-Mayén R. Factors associated with gender and sex differences in anxiety prevalence and comorbidity: a systematic review. Sci. Prog. 2022; 105(4): 368504221135469. https://dx.doi.org/10.1177/00368504221135469
24. MacKenzie G., Maguire J. The role of ovarian hormone-derived neurosteroids on the regulation of GABAA receptors in affective disorders. Psychopharmacology (Berl). 2014; 231(17): 3333-42. https://dx.doi.org/10.1007/s00213-013-3423-z
25. Fidecicchi T., Giannini A., Chedraui P., Luisi S., Battipaglia C., Genazzani A.R. et al. Neuroendocrine mechanisms of mood disorders during menopause transition: A narrative review and future perspectives. Maturitas. 2024; 188: 108087. https://dx.doi.org/10.1016/j.maturitas.2024.108087
26. Sun Q., Li G., Zhao F., Dong M., Xie W., Liu Q. et al. Role of estrogen in treatment of female depression. Aging (Albany NY). 2024; 16(3): 3021-42. https://dx.doi.org/10.18632/AGING.205507
27. Есин О.Р., Маштакова А.И., Есин Р.Г. ГАМКергическая система – физио­логическая роль и клиническое значение. Медицинский совет. 2025; 19(3): 118-26.
28. Карева Е.Н., Олейникова О.М., Панов В.О., Шимановский Н.Л., Скворцова В.И. Эстрогены и головной мозг. Вестник РАМН. 2012; 67(2): 48-59.
29. Fidecicchi T., Chedraui P., Luisi S., Battipaglia C., Genazzani A.R., Simoncini T. et al. Neuroendocrine mechanisms of mood disorders during menopause transition: a narrative review and future perspectives. Maturitas. 2024; 188: 108087. https://dx.doi.org/10.1016/j.maturitas.2024.108087
30. Domonkos E., Hodosy J., Ostatníková D., Celec P. On the role of testosterone in anxiety-like behavior across life in experimental rodents. Front. Endocrinol. (Lausanne). 2018; 9: 441. https://dx.doi.org/10.3389/fendo.2018.00441
31. Musial N., Ali Z., Grbevski J., Veerakumar A., Sharma P. Perimenopause and first-onset mood disorders: a closer look. Focus (Am. Psychiatr. Publ.). 2021; 19(3): 330-7. https://dx.doi.org/10.1176/appi.focus.20200041
32. Yue H., Yang Y., Xie F., Cui J., Li Y., Si M. et al. Effects of physical activity on depressive and anxiety symptoms of women in the menopausal transition and menopause: a comprehensive systematic review and meta-analysis of randomized controlled trials. Int. J. Behav. Nutr. Phys. Act. 2025; 22(1): 13. https://dx.doi.org/10.1186/s12966-025-01712-z
33. Juang K.D., Wang S.J., Lu S.R., Lee S.J., Fuh J.L. Hot flashes are associated with psychological symptoms of anxiety and depression in peri- and post- but not premenopausal women. Maturitas. 2005; 52(2): 119-26. https://dx.doi.org/10.1016/j.maturitas.2005.01.005
34. Wang S.J., Feng X., Zhang W., Sun G.Y., Fang H., Jing H. et al. Depression and anxiety in patients with breast cancer receiving radiotherapy: a longitudinal study. Ther. Adv. Med. Oncol. 2025; 17: 17588359251345930. https://dx.doi.org/10.1177/17588359251345930
35. Lee S., Jang M., Kim D., Kim K. Association between menopausal women's quality of life and aging anxiety: the role of life satisfaction and depression. Medicina (Kaunas). 2024; 60(8): 1189. https://dx.doi.org/10.3390/medicina60081189
36. Гаспарян С.А., Чотчаева А.М., Карпов С.М. Когнитивные и психоэмоциональные нарушения у женщин периода менопаузального перехода: возможности медикаментозной коррекции. Проблемы Эндокринологии. 2023; 69(1): 86-95.
37. Acar Ö., Goksel G., Ozan E., Altunbaş A.A., Karakaya M.S., Ekinci F., Erdoğan A.P. The psychosocial burden of breast cancer: a cross-sectional study of associations between sleep quality, anxiety, and depression in Turkish women. J. Clin. Med. 2025; 14(19): 6773. https://dx.doi.org/10.3390/jcm14196773
38. Penberthy J.K., Stewart A.L., Centeno C.F., Penberthy D.R. Psychological aspects of breast cancer. Psychiatr. Clin. North Am. 2023; 46(3): 551-70. https://dx.doi.org/10.1016/j.psc.2023.04.010
39. Fortin J., Leblanc M., Elgbeili G., Cordova M.J., Marin M.F., Brunet A. The mental health impacts of receiving a breast cancer diagnosis: a meta-analysis. Br. J. Cancer. 2021; 125(11): 1582-92. https://dx.doi.org/10.1038/s41416-021-01542-3
40. Panay N., Anderson R.A., Bennie A., Cedars M., Davies M., Ee C. et al. Evidence-based guideline: premature ovarian insufficiency. Climacteric. 2024; 27(6):510-20. https://dx.doi.org/10.1080/13697137.2024.2423213
41. Аверкова В.Г., Юренева С.В. Оценка качества жизни пациенток с преждевременной недостаточностью яичников, принимающих заместительную гормональную терапию. Акушерство и гинекология. 2023; 5: 50-8.
42. Feng P., Lin L., Wang Y., Chen L., Min J., Xie Y. et al. Impacts of menopause hormone therapy on mood disorders among postmenopausal women. Climacteric. 2022; 25(6): 579-85. https://dx.doi.org/10.1080/13697137.2022.2026915
43. Sullivan S.D., Sarrel P.M., Nelson L.M. Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause. Fertil Steril. 2016; 106(7): 1588-99. https://dx.doi.org/10.1016/j.fertnstert.2016.09.046
44. Nuss P., Ferreri F., Bourin M. An update on the anxiolytic and neuroprotective properties of etifoxine: from brain GABA modulation to a whole-body mode of action. Neuropsychiatr Dis Treat. 2019; 15: 1781-95. https://dx.doi.org/10.2147/NDT.S200568
45. Шнайдер Н.А., Макаров Е.А., Кидяева A.B., Гречкина В.В., Петрова М.М., Насырова Р.Ф. Селективные ингибиторы обратного захвата серотонина: проблема безопасности (систематический обзор). Забайкальский медицинский вестник. 2024; 4: 133-49.
46. Poisbeau P., Gazzo G., Calvel L. Anxiolytics targeting GABAA receptors: Insights on etifoxine. World J. Biol. Psychiatry. 2018; 19(sup1): S36-45. https://dx.doi.org/10.1080/15622975.2018.1468030
47. Stein D.J. Etifoxine versus alprazolam for the treatment of adjustment disorder with anxiety: a randomized controlled trial. Adv. Ther. 2015; 32(1): 57-68. https://dx.doi.org/10.1007/s12325-015-0176-6
48. do Rego J.L., Vaudry D., Vaudry H. The non-benzodiazepine anxiolytic drug etifoxine causes a rapid, receptor-independent stimulation of neurosteroid biosynthesis. PLoS One. 2015; 10(3): e0120473. https://dx.doi.org/10.1371/journal.pone.0120473
49. Vicente B., Saldivia S., Hormazabal N., Bustos C., Rubí P. Etifoxine is non-inferior than clonazepam for reduction of anxiety symptoms in the treatment of anxiety disorders: a randomized, double blind, non-inferiority trial. Psychopharmacology (Berl). 2020; 237(11): 3357-67. https://dx.doi.org/10.1007/s00213-020-05617-6
50. Nguyen N., Fakra E., Pradel V., Jouve E., Alquier C., Le Guern M.E. et al. Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice. Hum. Psychopharmacol. 2006; 21(3): 139-49. https://dx.doi.org/10.1002/hup.757
51. Deplanque D., Machuron F., Waucquier N., Jozefowicz E., Duhem S., Somers S. et al. Etifoxine impairs neither alertness nor cognitive functions of the elderly: A randomized, double-blind, placebo-controlled crossover study. Eur. Neuropsychopharmacol. 2018; 28(8): 925-32. https://dx.doi.org/10.1016/j.euroneuro.2018.05.011
52. Торшин И.Ю., Громова О.А., Федотова Л.Э., Громов А.Н. Эффекты этифоксина (хемореактомное моделирование). Неврология, нейропсихиатрия, психосоматика. 2016; 8(2): 44-9.

Поступила 10.12.2025

Принята в печать 18.12.2025